Systemic In ammatory Index: A Novel Biomarker for Predicting the Progression in Active Surveillance in Patients with Prostate Cancer | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2023]

Author(s):

1. Levent Ozcan: Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital,Istanbul,Turkey

2. Memik Omur: Department of Urology, University of Health Sciences, Derince Training and Research Hospital,Kocaeli,Turkey

3. Emre Can Polat: Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital,Istanbul,Turkey

4. Caner Baran: Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital,Istanbul,Turkey

5. Ahmet Boylu: Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital,Istanbul,Turkey

6. Alper Otunctemur: Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital,Istanbul,Turkey

Abstract:

Objective: To investigate active surveillance (AS) for patients with prostate cancer to show the systemic in ammatory index (SII) progression and to evaluate whether SII will be an AS criterion in PCa patients. Study Design: Descriptive study. Place and Duration of the Study: Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, from February 2015 to December 2021. Methodology: For active surveillance follow-up criteria, patients with prostate cancer who underwent AS with PSA 443.42) had better explanations for progression than the number of core involvement but were similar to the length of the tumour in one core. As a result of the multivariate analysis, high SII values (>443.42) and the tumour 's length in one core had similar e ects on progression (in order of p = 0.011, B = 1.978, Exp(B) = 7.227, CI [1.570 33.269]; p = 0.009, B = 1.958, Exp(B) = 7.084, CI [1.642 30.555]). Conclusion: Th use of SII early in the course of treatment can help to identify which prostate cancer patients can be selected for active treatment instead of active surveillance, and to assess the probability of progression.

Page(s): 1278-1282

DOI: 10.29271/jcpsp.2023.11.1278

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 11, Year: 2023

Keywords:

Biomarker , Prostate cancer , Systemic in ammatory index , Active surveillance

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views